📊 JANX Key Takeaways
Is Janux Therapeutics, Inc. (JANX) a Good Investment?
Janux Therapeutics is a pre-revenue biotech company with severe cash burn (-$82.2M operating cash flow) and only $52.3M in cash reserves, implying a runway of approximately 6-8 months at current burn rates. The company is deeply unprofitable (-$113.6M net loss) with negative margins exceeding -1000%, characteristic of a clinical-stage pharmaceutical firm with no commercialized products and no clear path to profitability in the near term.
Janux Therapeutics shows very strong balance-sheet quality, with nearly $957M of equity, minimal liabilities, no meaningful debt, and exceptionally high liquidity that supports ongoing R&D funding. However, the business remains deeply unprofitable, with extremely negative operating and net margins, declining revenue, and significant cash burn, so the core fundamental case still depends on future pipeline execution rather than current operating performance.
Why Buy Janux Therapeutics, Inc. Stock? JANX Key Strengths
- Strong balance sheet with minimal debt ($0M long-term debt) and low leverage (0.00x D/E ratio)
- Excellent liquidity position with 39.04x current ratio, providing operational flexibility
- Substantial equity cushion of $956.8M providing strategic flexibility for R&D and potential partnerships
- Exceptional liquidity with current and quick ratios of 39.04x
- Very strong capitalization with $956.82M in equity and negligible leverage
- Large asset base and low liabilities provide flexibility to sustain development spending
JANX Stock Risks: Janux Therapeutics, Inc. Investment Risks
- Severe cash burn rate of $82.2M annually against only $52.3M in cash equivalents indicates imminent need for capital raise or strategic action
- No revenue generation with only $10.0M reported (likely from grants/milestone payments) insufficient to offset operating losses
- Critical funding risk: current cash runway of 6-8 months at observed burn rates creates existential liquidity pressure and risk of equity dilution
- Operating and net margins of -1576.7% and -1136.2% respectively reflect highly unprofitable pre-commercial operations typical of high-risk biotech
- Severe ongoing losses with operating income of -$157.67M and net margin of -1136.2%
- Negative free cash flow of -$83.28M indicates continued cash burn
- Revenue base is small and declined 5.6% YoY, limiting evidence of durable commercial traction
Key Metrics to Watch
- Cash and equivalents balance and runway (critical near-term survival metric)
- Quarterly operating cash burn rate and trajectory
- Clinical trial progress and regulatory milestones for pipeline programs
- Capital raise announcements and terms (equity dilution risk)
- R&D spending efficiency and pipeline advancement
- Quarterly operating cash burn relative to cash reserves
- Revenue growth quality from collaborations, milestones, or product commercialization progress
Janux Therapeutics, Inc. (JANX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 39.04x current ratio provides a solid financial cushion.
JANX Profit Margin, ROE & Profitability Analysis
JANX vs Healthcare Sector: How Janux Therapeutics, Inc. Compares
How Janux Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Janux Therapeutics, Inc. Stock Overvalued? JANX Valuation Analysis 2026
Based on fundamental analysis, Janux Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Janux Therapeutics, Inc. Balance Sheet: JANX Debt, Cash & Liquidity
JANX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Janux Therapeutics, Inc.'s revenue has grown significantly by 191% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.32 indicates the company is currently unprofitable.
JANX Revenue Growth, EPS Growth & YoY Performance
JANX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $439.0K | -$24.3M | $-0.39 |
| Q2 2025 | N/A | -$6.0M | $-0.11 |
| Q1 2025 | N/A | -$14.8M | $-0.30 |
| Q3 2024 | $439.0K | -$11.6M | $-0.25 |
| Q2 2024 | $1.1M | -$6.0M | $-0.11 |
| Q1 2024 | $1.3M | -$14.8M | $-0.30 |
| Q3 2023 | $1.8M | -$11.6M | $-0.25 |
| Q2 2023 | $1.1M | -$16.9M | $-0.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Janux Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
JANX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Janux Therapeutics, Inc. (CIK: 0001817713)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JANX
What is the AI rating for JANX?
Janux Therapeutics, Inc. (JANX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are JANX's key strengths?
Claude: Strong balance sheet with minimal debt ($0M long-term debt) and low leverage (0.00x D/E ratio). Excellent liquidity position with 39.04x current ratio, providing operational flexibility. ChatGPT: Exceptional liquidity with current and quick ratios of 39.04x. Very strong capitalization with $956.82M in equity and negligible leverage.
What are the risks of investing in JANX?
Claude: Severe cash burn rate of $82.2M annually against only $52.3M in cash equivalents indicates imminent need for capital raise or strategic action. No revenue generation with only $10.0M reported (likely from grants/milestone payments) insufficient to offset operating losses. ChatGPT: Severe ongoing losses with operating income of -$157.67M and net margin of -1136.2%. Negative free cash flow of -$83.28M indicates continued cash burn.
What is JANX's revenue and growth?
Janux Therapeutics, Inc. reported revenue of $10.0M.
Does JANX pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
Where can I find JANX SEC filings?
Official SEC filings for Janux Therapeutics, Inc. (CIK: 0001817713) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JANX's EPS?
Janux Therapeutics, Inc. has a diluted EPS of $-1.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JANX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Janux Therapeutics, Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JANX stock overvalued or undervalued?
Valuation metrics for JANX: ROE of -11.9% (sector avg: 15%), net margin of -1,136.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JANX stock in 2026?
Our dual AI analysis gives Janux Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JANX's free cash flow?
Janux Therapeutics, Inc.'s operating cash flow is $-82.2M, with capital expenditures of $1.0M. FCF margin is -832.8%.
How does JANX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,136.3% (avg: 12%), ROE -11.9% (avg: 15%), current ratio 39.04 (avg: 2).